The Valora Rx Journal
Physician-reviewed guides on semaglutide and tirzepatide, testosterone and HRT, BPC-157 and the rest of the peptide library — grounded in primary research, written for patients.
Showing 27 articles
Used in 30+ countries for chronic viral infection, immune dysfunction, and as a cancer adjunct. Here's what the evidence actually shows and where Valora uses it.
Oral NMN, subcutaneous NAD+, IV NAD+ — they all aim to raise the same cellular cofactor, but the routes and evidence differ substantially.
PT-141 works in the brain; PDE5 inhibitors work in the blood vessels. The mechanism difference determines which patients benefit from which therapy.
A clinician's view of how the most-prescribed peptides combine — what works together, what doesn't, and what to skip entirely.
The most popular growth-hormone-stimulating peptide stack in clinical practice. Here's what each component does, why they're paired, and what to expect.
Both are healing peptides, both used by athletes — but the mechanisms and best-fit injuries are different. Here's how clinicians choose between them.
The cognitive symptoms of perimenopause are real, measurable, and biologically driven — not a psychological reaction. Here's what's happening and what helps.
Aromatase inhibitors are overprescribed in TRT. Here's the evidence on when estradiol actually needs to come down and when it's healthier to leave it alone.
Testosterone replacement suppresses sperm production within months. HCG and selective protocols can preserve fertility — here's how the biology and the medication interact.
Every delivery method for menopausal hormone therapy has trade-offs. Here's the evidence on absorption, dosing precision, safety, and which patients fit each option.
Fatigue, low libido, brain fog — every symptom of low testosterone overlaps with something else. Here's how to distinguish hypogonadism from the alternatives.
Ashwagandha, zinc, sleep, and resistance training can move testosterone — but how much, and for whom? Here's where lifestyle ends and replacement begins.
Sub-therapeutic GLP-1 dosing has become a popular maintenance and longevity strategy. Here's where the evidence supports it and where it gets ahead of the data.
Roughly 25–40% of weight lost on a GLP-1 is lean mass. Here's what that means clinically, and the protein and training protocol that protects it.
The data is clear: stop GLP-1s cold and most patients regain. Here's the evidence on maintenance protocols, microdosing, and the metabolic transition off therapy.
Wegovy, Zepbound, and compounded semaglutide all contain the same active molecule — but they're not the same product. Here's what changes and what doesn't.
BMI thresholds, comorbidities, contraindications — a clear breakdown of who is a candidate for semaglutide or tirzepatide and who is not.
Nausea, constipation, fatigue — the most common GLP-1 side effects are predictable, time-limited, and largely manageable with the right protocol.
Two of the most powerful weight loss medications available today work differently — here's how to know which one fits your body, goals, and history.
Testosterone replacement isn't a switch you flip. Here's an honest, week-by-week look at how your body, energy, and mood actually shift.
Athletes whisper about it. Physicians are paying attention. Here's what the research actually says about BPC-157 and tissue repair.
NAD+ is foundational to how your cells produce energy — and it declines with age. Here's what supplementation can and can't do.
Symptoms can start a decade before menopause — and most women are told it's stress. Here's what's actually happening, and what can be done.
Unlike most sexual wellness medications, PT-141 acts on the central nervous system. Here's what makes it different — and who it's for.
Most patients hit a weight loss plateau on semaglutide or tirzepatide. It's not failure — it's biology. Here's the playbook for getting moving again.
The telehealth market is crowded. Here's how to tell a serious clinical operation from a prescription mill — in five questions.